560 related articles for article (PubMed ID: 33655500)
41. Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.
Pizarro M; Solís N; Quintero P; Barrera F; Cabrera D; Rojas-de Santiago P; Arab JP; Padilla O; Roa JC; Moshage H; Wree A; Inzaugarat E; Feldstein AE; Fardella CE; Baudrand R; Riquelme A; Arrese M
Liver Int; 2015 Sep; 35(9):2129-38. PubMed ID: 25646700
[TBL] [Abstract][Full Text] [Related]
42. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis.
Hansen HH; Ægidius HM; Oró D; Evers SS; Heebøll S; Eriksen PL; Thomsen KL; Bengtsson A; Veidal SS; Feigh M; Suppli MP; Knop FK; Grønbæk H; Miranda D; Trevaskis JL; Vrang N; Jelsing J; Rigbolt KTG
BMC Gastroenterol; 2020 Jul; 20(1):210. PubMed ID: 32631250
[TBL] [Abstract][Full Text] [Related]
43. Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
Møllerhøj MB; Veidal SS; Thrane KT; Oró D; Overgaard A; Salinas CG; Madsen MR; Pfisterer L; Vyberg M; Simon E; Broermann A; Vrang N; Jelsing J; Feigh M; Hansen HH
Clin Transl Sci; 2022 May; 15(5):1167-1186. PubMed ID: 35143711
[TBL] [Abstract][Full Text] [Related]
44. Periostin antisense oligonucleotide prevents hepatic steatosis and fibrosis in a mouse model of non-alcoholic steatohepatitis.
Kobayashi T; Kanno K; Nguyen PT; Sugiyama A; Kawahara A; Otani Y; Kishikawa N; Ito M; Tazuma S
J Gastroenterol Hepatol; 2020 Dec; 35(12):2140-2150. PubMed ID: 32365405
[TBL] [Abstract][Full Text] [Related]
45. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
[TBL] [Abstract][Full Text] [Related]
46. The Influence of Emodin Succinyl Ethyl Ester on Non-alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice.
Wang Y; Li L; Chen L; Xia J; Wang T; Han L; Cao L; Wang Z; Xiao W; Jiang S
Biol Pharm Bull; 2024 May; 47(5):978-987. PubMed ID: 38631865
[TBL] [Abstract][Full Text] [Related]
47. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
[TBL] [Abstract][Full Text] [Related]
48. Bouchardatine analogue alleviates non-alcoholic hepatic fatty liver disease/non-alcoholic steatohepatitis in high-fat fed mice by inhibiting ATP synthase activity.
Rao Y; Lu YT; Li C; Song QQ; Xu YH; Xu Z; Hu YT; Yu H; Gao L; Gu LQ; Ye JM; Huang ZS
Br J Pharmacol; 2019 Aug; 176(16):2877-2893. PubMed ID: 31113010
[TBL] [Abstract][Full Text] [Related]
49. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis.
Kohli R; Kirby M; Xanthakos SA; Softic S; Feldstein AE; Saxena V; Tang PH; Miles L; Miles MV; Balistreri WF; Woods SC; Seeley RJ
Hepatology; 2010 Sep; 52(3):934-44. PubMed ID: 20607689
[TBL] [Abstract][Full Text] [Related]
50. Consumption of Low Dose Fucoxanthin Does Not Prevent Hepatic and Adipose Inflammation and Fibrosis in Mouse Models of Diet-Induced Obesity.
Kim MB; Bae M; Lee Y; Kang H; Hu S; Pham TX; Park YK; Lee JY
Nutrients; 2022 May; 14(11):. PubMed ID: 35684079
[TBL] [Abstract][Full Text] [Related]
51. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy.
Kristiansen MN; Veidal SS; Rigbolt KT; Tølbøl KS; Roth JD; Jelsing J; Vrang N; Feigh M
World J Hepatol; 2016 Jun; 8(16):673-84. PubMed ID: 27326314
[TBL] [Abstract][Full Text] [Related]
52. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
53. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
[TBL] [Abstract][Full Text] [Related]
54. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.
Krishnan A; Abdullah TS; Mounajjed T; Hartono S; McConico A; White T; LeBrasseur N; Lanza I; Nair S; Gores G; Charlton M
Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G666-G680. PubMed ID: 28232454
[TBL] [Abstract][Full Text] [Related]
55. Vitronectin deficiency attenuates hepatic fibrosis in a non-alcoholic steatohepatitis-induced mouse model.
Hayashida M; Hashimoto K; Ishikawa T; Miyamoto Y
Int J Exp Pathol; 2019 Apr; 100(2):72-82. PubMed ID: 30887659
[TBL] [Abstract][Full Text] [Related]
56. A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology.
van den Hoek AM; Verschuren L; Worms N; van Nieuwkoop A; de Ruiter C; Attema J; Menke AL; Caspers MPM; Radhakrishnan S; Salic K; Kleemann R
Cells; 2020 Sep; 9(9):. PubMed ID: 32883049
[TBL] [Abstract][Full Text] [Related]
57. Astaxanthin inhibits inflammation and fibrosis in the liver and adipose tissue of mouse models of diet-induced obesity and nonalcoholic steatohepatitis.
Kim B; Farruggia C; Ku CS; Pham TX; Yang Y; Bae M; Wegner CJ; Farrell NJ; Harness E; Park YK; Koo SI; Lee JY
J Nutr Biochem; 2017 May; 43():27-35. PubMed ID: 28193580
[TBL] [Abstract][Full Text] [Related]
58. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
[TBL] [Abstract][Full Text] [Related]
59. Neferine ameliorates nonalcoholic steatohepatitis through regulating AMPK pathway.
Wang MY; Zhang SS; An MF; Xia YF; Fan MS; Sun ZR; Zhang LJ; Zhao YL; Sheng J; Wang XJ
Phytomedicine; 2023 Jun; 114():154798. PubMed ID: 37031639
[TBL] [Abstract][Full Text] [Related]
60. Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis.
Mells JE; Fu PP; Kumar P; Smith T; Karpen SJ; Anania FA
J Nutr Biochem; 2015 Mar; 26(3):285-92. PubMed ID: 25577467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
